Gold prices buoyed by tariff fears; US duties on 1-kilo bars spur supply concerns
On Tuesday, Goldman Sachs adjusted its stance on AbbVie shares (NYSE:ABBV), downgrading the stock to a Neutral rating from a previous Buy. The firm also revised its price target to $194 from $212. The stock has experienced a significant 9.56% decline over the past week, with InvestingPro data showing the stock is currently in oversold territory based on RSI indicators. Despite recent volatility, AbbVie maintains strong fundamentals with a "GOOD" overall financial health score. The downgrade reflects a market consensus that now aligns with management's guidance, acknowledging the fully appreciated growth of AbbVie's key immunology drugs, Skyrizi and Rinvoq. With a substantial market capitalization of $330 billion and revenue growth of 3.71% in the last twelve months, AbbVie continues to demonstrate its market leadership position.
Goldman Sachs highlighted that these two drugs have been significant contributors to AbbVie's revenue, but with their success now well recognized by the market, the potential for positive surprises may rely on other segments of the company's portfolio. The firm anticipates a more challenging environment for these areas in the near term.
In particular, the Aesthetics franchise, which accounts for approximately 10% of AbbVie's total revenues, is expected to face ongoing difficulties. These challenges are attributed to broader economic pressures such as inflation and reduced consumer sentiment, which may weigh more heavily on the business due to increased recession risks as indicated by Goldman Sachs economists.
Additionally, the firm's due diligence with Key Opinion Leaders (KOLs) suggests growing competitive pressures in the injectable aesthetics market. Concerns were also raised about potential commercialization risks associated with AbbVie's novel rapid-acting Botox formulation, BonT/E, intended for severe glabellar lines treatment. For investors seeking deeper insights, InvestingPro offers comprehensive analysis of AbbVie's competitive position and market dynamics, including 13 additional ProTips and detailed valuation metrics. Despite being positioned by AbbVie's management as a significant innovation that could expand the neurotoxin market and increase Botox market share, Goldman Sachs seems cautious about its immediate impact.
The revised price target and stock rating reflect Goldman Sachs' current analysis of AbbVie's portfolio and market conditions, with an emphasis on the lack of major pipeline catalysts and the potential headwinds facing the Aesthetics division. Despite these challenges, AbbVie maintains a strong dividend yield of 3.52% and has raised its dividend for 12 consecutive years, demonstrating consistent shareholder returns. According to InvestingPro's Fair Value analysis, the stock appears to be trading near its fair value.
In other recent news, AbbVie has made several strategic moves that are capturing investor attention. AbbVie announced a licensing agreement with Gubra for a long-acting Amylin analogue, GUB14295, currently in phase 1 development. This agreement involves an upfront payment of $350 million and potential milestone payments of up to $1.875 billion, along with royalties on net sales. BMO Capital Markets maintained its Outperform rating for AbbVie with a price target of $215, reflecting confidence in the company's strategic direction. Erste Group upgraded AbbVie stock from Hold to Buy, citing robust sales growth forecasts and a promising pipeline of new products. AbbVie has projected a significant increase in earnings per share for 2025, ranging from $12.12 to $12.32. Berenberg also raised its price target for AbbVie shares from $165 to $195, while maintaining a Hold rating, based on revised earnings forecasts and strong immunology sales. These developments highlight AbbVie's proactive approach in expanding its product portfolio and strategic positioning in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.